Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Other Non-Current Assets (2016 - 2025)

Niagen Bioscience (NAGE) has disclosed Other Non-Current Assets for 13 consecutive years, with $425000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Other Non-Current Assets rose 15.49% to $425000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $425000.0, a 15.49% increase, with the full-year FY2025 number at $425000.0, up 15.49% from a year prior.
  • Other Non-Current Assets was $425000.0 for Q4 2025 at Niagen Bioscience, up from $152000.0 in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $576000.0 in Q3 2021 to a low of $152000.0 in Q4 2021.
  • A 5-year average of $222466.7 and a median of $152000.0 in 2021 define the central range for Other Non-Current Assets.
  • Peak YoY movement for Other Non-Current Assets: skyrocketed 188.0% in 2021, then tumbled 65.28% in 2022.
  • Niagen Bioscience's Other Non-Current Assets stood at $152000.0 in 2021, then changed by 0.0% to $152000.0 in 2022, then changed by 0.0% to $152000.0 in 2023, then soared by 142.11% to $368000.0 in 2024, then grew by 15.49% to $425000.0 in 2025.
  • Per Business Quant, the three most recent readings for NAGE's Other Non-Current Assets are $425000.0 (Q4 2025), $152000.0 (Q2 2025), and $368000.0 (Q4 2024).